Risk of Herpes Zoster Ophthalmicus Recurrence After Recombinant Zoster Vaccination.

ABSTRACT:

Importance

The recombinant zoster vaccine (RZV) is currently recommended for immunocompetent adults aged 50 years or older and immunocompromised adults aged 19 years or older and is effective in preventing herpes zoster ophthalmicus (HZO). However, questions about the safety of RZV in patients with a history of HZO remain.

Objective

To evaluate whether there is an increased risk of HZO recurrence after RZV in patients with a history of HZO.

Design, setting, and participants

This retrospective cohort study used medical and outpatient pharmacy claims data for commercial and Medicare Advantage enrollees from the Optum Labs Data Warehouse. Patients with incident HZO from January 1, 2010, to December 31, 2021, were identified; the study period ended on March 31, 2022. The

SUBMITTER: Walia A 

PROVIDER: S-EPMC10870220 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature